Matthieu Roulleaux Dugage

机构：Inserm, Université Paris-Saclay, Institut Gustave Roussy, Hôpital Européen Georges-Pompidou, Hôpital Européen · ORCID：0000-0003-3192-2342

发表论文 46 篇 · 总被引 308 次 · h-index 7

代表论文

• Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials (2024 · Cancers · 被引 4)
• 1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial (2025 · 被引 2)
• 157P Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC) (2024 · Immuno-Oncology Technology · 被引 2)
• VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC (2026 · Journal for ImmunoTherapy of Cancer · 被引 1)
• Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants. (2025 · Journal of Clinical Oncology · 被引 1)
• Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit (2026 · European Journal of Cancer)